Pharmaceuticals 23 February 2026

Pfizer Stock Price Today: Shares Slip After GSK RSV Move Offsets Eliquis Data

Pfizer Inc. slipped about 1% to close at $26.60 on Friday, landing near the session’s low as investors digested fresh developments in the respiratory syncytial virus vaccine landscape and a boost for blood thinner Eliquis. The pressure came after GSK announced the FDA had expanded Arexvy’s approval to include at-risk adults 18 to 49. Meanwhile, separate results highlighted strong outcomes for Eliquis in treating serious blood clots.

13 March 2026

NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)

Pfizer ended Thursday down 1.6% at $26.86, caught up in a sweeping selloff across U.S. equities. Oil prices jumped on intensifying Middle East tensions, and the slide hit all three major indexes—S&P 500, Dow, and Nasdaq—each losing over 1.5%.

12 March 2026

NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Pfizer Stock Price Today: PFE Slips as mRNA Vaccine Worry Eases, Eczema Data Offers Fresh Catalyst

Pfizer slipped roughly 0.4% to $27.05 midday Wednesday in New York. Investors reacted after the Washington Post said U.S. vaccine advisers scrapped plans to scrutinize mRNA COVID vaccines, removing a potential regulatory obstacle for the company’s vaccine segment.

11 March 2026

NYSE:PFE·Pfizer News·Pharmaceuticals·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Pfizer eczema drug clears Phase 2, sets up a fresh challenge to Dupixent

Pfizer’s experimental eczema treatment, tilrekimig, hit its main target in a mid-stage trial, the company said Monday. That outcome sets up a late-stage study slated for later this year, pushing Pfizer nearer to a market still dominated by Sanofi and Regeneron’s Dupixent.

9 March 2026

NYSE:PFE·Pharmaceuticals

GSK steps up share buyback as fresh annual report spells out CEO Luke Miels’ 2026 priorities

GSK picked up 650,000 shares on Thursday for its buyback, paying prices from 2,072 pence up to 2,135 pence apiece. Those shares are headed for treasury, according to the company.

6 March 2026

LSE:GSK·Pharmaceuticals·Stock Market

Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson slipped roughly 0.7% Wednesday, even as the company announced its lupus drug candidate nipocalimab received Fast Track designation from the U.S. FDA. Shares traded at $245.07, down $1.68 in the afternoon session.

4 March 2026

NYSE:JNJ·Pharmaceuticals·Stock Market

GSK share price today: stock edges up after $2.2 billion RAPT deal closes and buyback rolls on

GSK edged up 0.8% to 2,138 pence as of 0947 GMT on Wednesday, clawing back some losses from the previous session, after the company said it wrapped up its acquisition of RAPT Therapeutics. The most recent closing price, according to delayed data, was 2,122 pence.

4 March 2026

LSE:GSK·Pharmaceuticals·Stock Market

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly and Company wrapped up Tuesday’s session down roughly 1%, settling at $1,007.73. That followed a 3.23% drop the previous day.

4 March 2026

NASDAQ:VTYX·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly and Company shares slipped 2.3% to $1,028.07 in Monday afternoon trading. Earlier in the session, the stock climbed as high as $1,056.84 but also dropped to $1,023.50 at its lowest. The drugmaker now holds a market value near $686 billion.

2 March 2026

HKG:1801·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Merck stock: weekend Keytruda-Welireg data and Gardasil cuts set up Monday trade

Merck & Co shares kick off the week in focus, following Friday’s rally. Investors are parsing through a batch of weekend cancer trial updates and a newly set U.S. FDA review schedule.

28 February 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly stock snaps skid on orforglipron pill data as April FDA clock nears

Shares of Eli Lilly and Company jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slump and pulling ahead of a broader market that dropped. The S&P 500 slipped 0.43%, while the Dow lost 1.05%, as traders grappled with stretched valuations and renewed jitters over the speed of artificial intelligence’s impact on market leaders and laggards.

28 February 2026

Biotechnology·NYSE:LLY·Pharmaceuticals·Stock Market

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK plc shares edged higher Friday morning, gaining 0.74% to 2,183 pence by 0855 GMT, as investors parsed several pipeline updates from the last 48 hours.

27 February 2026

LSE:GSK·Pharmaceuticals·Stock Market

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Celldex Therapeutics dropped about 4% to $29.58 in premarket action Thursday, paring gains after the stock soared 24% to close at $30.82 the previous session.

26 February 2026

NASDAQ:CLDX·Pharmaceuticals·Stock Market

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly and Company ended Wednesday’s session off 1.28% at $1,028.83, with traders once again zeroing in on the obesity-drug story instead of the wider market action.

26 February 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

GSK shares nudge up on $950 mln 35Pharma deal as dealmaking picks up

GSK ticked up Wednesday, following its $950 million cash deal to acquire Canada’s 35Pharma and take on an in-development pulmonary hypertension therapy.

25 February 2026

LSE:GSK·Pharmaceuticals

Dianthus Therapeutics (DNTH) stock rises ahead of TD Cowen conference; what investors watch next

Dianthus Therapeutics Inc drew attention before Tuesday’s U.S. open, with the biotech announcing plans to present at TD Cowen’s health care conference next week.

24 February 2026

NASDAQ:DNTH·Pharmaceuticals·Stock Market

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk dropped 2.5% to 245.1 Danish crowns on Tuesday. The stock continued to slide after the company’s next-generation obesity drug, CagriSema, delivered underwhelming trial results.

24 February 2026

NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly jumped roughly 4.9% to $1,058.23 late Monday, after Novo Nordisk revealed its next-gen obesity candidate, CagriSema, didn’t measure up to Lilly’s Zepbound in direct comparison. Novo's U.S. shares dropped sharply, sliding 16.4% to $39.63.

23 February 2026

Biotechnology·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus

Organon & Co shares jumped roughly 7.8% in premarket action Monday, hitting $8.10.

23 February 2026

NYSE:OGN·Pharmaceuticals·Stock Market

Pharmaceuticals 23 February 2026 - 13 March 2026